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Abstract
 
Hematopoietic stem cells (HSC) give rise to cells of all hematopoietic lineages, many of which
are short lived. HSC face developmental choices: self-renewal (remain an HSC with long-term
multilineage repopulating potential) or differentiation (become an HSC with short-term multi-
lineage repopulating potential and, eventually, a mature cell). There is a large overcapacity of
differentiating hematopoietic cells and apoptosis plays a role in regulating their numbers. It is
not clear whether apoptosis plays a direct role in regulating HSC numbers. To address this, we
have employed a transgenic mouse model that overexpresses BCL-2 in all hematopoietic cells,
including HSC: H2K-
 
BCL
 
-2. Cells from H2K-
 
BCL
 
-2 mice have been shown to be protected
against a wide variety of apoptosis-inducing challenges. This block in apoptosis affects their
HSC compartment. H2K-
 
BCL
 
-2–transgenic mice have increased numbers of HSC in bone
marrow (2.4
 
3 
 
wild type), but fewer of these cells are in the S/G
 
2
 
/M phases of the cell cycle
(0.6
 
3
 
 wild type). Their HSC have an increased plating efficiency in vitro, engraft at least as
well as wild-type HSC in vivo, and have an advantage following competitive reconstitution
with wild-type HSC.
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Introduction
 
The hematopoietic system produces large numbers of ma-
ture cells each day, a capacity it retains throughout life
through the presence of hematopoietic stem cells (HSC).
 
1
 
A careful balance between self-renewal and differentiation
is necessary to maintain both HSC, which are relatively
constant throughout life, and adequate numbers of mature
cells. Different models, like clonal succession, have been
proposed to describe how this might be achieved. 5-Bromo-
2
 
9
 
-deoxyuridine labeling in vivo has recently shown that all
HSC in mice are constantly going in and out of cell cycle,
such that in any given month virtually all HSC divide (1,
2). In view of the proliferative capacity of both multipotent
and committed progenitors, a small fraction of the cells
produced by cell division of HSC with long-term multilin-
eage reconstituting potential (LT-HSC) is sufficient to pro-
duce all the mature hematopoietic cells needed to maintain
the organism. Yet the numbers of HSC, while increasing
somewhat with age in mice (3), remain fairly similar through-
out adult life. This overcapacity, which allows emergency
responses, means that regulation of hematopoietic cell pro-
duction is necessary to maintain homeostasis. For the more
primitive cell populations, such as HSC, this can in princi-
ple be accomplished by adjusting the balance between self-
renewal and differentiation. For the more mature compart-
ments, apoptosis plays an important role as well (4–7). It is
currently not clear whether apoptosis plays a similarly im-
portant and direct role in homeostasis of hematopoietic
stem cell numbers in vivo
 
 
 
(8).
In recent years, the importance of apoptosis in both nor-
mal and pathological physiology has become increasingly
clear, and large numbers of genes and their encoded pro-
teins have been characterized with respect to their role in
apoptosis (e.g., 9–12). 
 
Bcl
 
-2 (13–15) was the first identified
regulator of cell death (16). It belongs to a family whose
members both help protect against the induction of apop-
tosis (e.g., 
 
Bcl
 
-2 and 
 
Bcl
 
-x
 
L
 
) and help induce it (e.g., 
 
Bax
 
and 
 
Bad
 
) (9). Overexpression of both 
 
Bcl
 
-2 and 
 
Bcl
 
-x
 
L
 
 in
transgenic mice has demonstrated their ability to block ap-
optosis induced by many, but not all, stimuli. Some of the
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Abbreviations used in this paper:
 
 HSC, hematopoietic stem cell(s); LT-
HSC, long-term hematopoietic stem cell(s); ST-HSC, short-term hema-
topoietic stem cell(s); WBM, whole bone marrow; WT, wild-type. 
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apoptotic stimuli that are blocked partially at best include
CTL-induced killing (17, 18) and FAS-induced apoptosis
(19–21). In addition, it has been documented that aberrant
expression of members of the 
 
Bcl
 
-2 family affects the cell
cycle. Overexpression of those members of the family that
protect against induced apoptosis lengthens the cell cycle (22),
while overexpression of proapoptotic members has the op-
posite effect (23).
The consequences of blocking programmed cell death
have been studied in transgenic mice overexpressing 
 
Bcl
 
-2 or
 
Bcl
 
-x
 
L
 
 (4–7). These studies have demonstrated that blocking
cell death leads to perturbations in cell populations and can
contribute to the development of malignancies and auto-
immune disease. It does not prevent negative selection dur-
ing lymphocyte maturation. Overexpression of 
 
Bcl
 
-2 has re-
vealed an unexpected limited role, regulating survival rather
then guiding proliferation and differentiation for some cy-
tokines (7, 24–27). Although 
 
Bcl
 
-2 has been overexpressed
in early hematopoietic progenitor cells in vitro (24), it has
not been targeted to HSC in vivo. To achieve this, we have
recently generated a transgenic mouse in which the human
 
BCL
 
-2 is overexpressed under control of the well-charac-
terized mouse H-2K
 
b
 
 promoter, combined with the Molo-
ney murine leukemia virus LTR. This promoter is expressed
at high levels in HSC (28–30) and many other tissues. We
have reported that H2K-
 
BCL
 
-2 transgenic mice express
high levels of human BCL-2 protein in all hematopoietic
lineages, including HSC. As a consequence of this, multiple
cell populations, including HSC of H2K-
 
BCL
 
-2–trans-
genic mice, are protected against lethal challenges such as
total body irradiation, which results in increased resistance
of the organism as a whole (30).
The high level of overexpression of functional BCL-2
protein in HSC of H2K-
 
BCL
 
-2–transgenic mice allows us
to evaluate directly the role of apoptosis in the regulation
of HSC numbers in vivo. This involves both the study of
the effect of a block on apoptosis on HSC maintenance, as
well as determining the ability of these cells to reconstitute
lethally irradiated hosts. The increase in HSC in vivo, and
the increased plating efficiency in vitro and reconstitution
capability in vivo demonstrate directly that apoptosis is an
important mechanism for limiting HSC numbers.
 
Materials and Methods
 
Mouse Strains.
 
H2K-
 
BCL
 
-2–transgenic mice were derived as
described (30). In brief, the transgenic construct contains a hu-
man 
 
BCL
 
-2 cDNA fragment cloned into the expression vector
H2K-i-LTR. This vector expresses cDNAs under control of the
H2K-promoter/enhancer and Moloney MuLV enhancer/poly(A)
site. This construct was introduced into zygotes from crosses be-
tween F1(C57BL/6 
 
3
 
 C3H). Mice that were positive by South-
ern blot analysis were backcrossed onto C57Bl/Ka, Thy-1.1, and
CD45.2 (H-2
 
b
 
). The transgene was followed in later generations
by flow cytometric screening for expression of the human BCL-2
protein in peripheral blood cells. Mice used in this study were
backcrossed at least five times onto C57Bl/Ka and were con-
firmed to be homozygous for Thy-1.1 by flow cytometry. Three
 
independent founderlines (1038, 1043, and 1053) were used in
this study. Congenic mice C57Bl/Ka, (Thy1.1, CD45.2), C57Bl/Ka
(Thy1.1, CD45.1), and the F1 crosses were bred at the animal
care facility at the Stanford University School of Medicine. All
mice were maintained on acidified water, pH
 
 
 
2.5.
 
Irradiation.
 
The lethal preconditioning regimen for HSC and
bone marrow reconstitution was 9.5 Gy total body irradiation,
given in two doses with a 3-h interval using a 200-kV x-ray ma-
chine. Mice were given antibiotic water (1.1 g/liter neomycin
sulfate and 10
 
6
 
 U/liter polymyxin B sulfate) for at least 8 wk after
irradiation to reduce the chance of infection from opportunistic
pathogens. Mice used for irradiation were 8–12 wk old.
 
Tissue Culture.
 
AC11 bone marrow stroma cells were cultured
in RPMI 1640 with 5% FCS, 5 
 
3
 
 10
 
2
 
5
 
 M 
 
b
 
-mercaptoethanol,
penicillin, and streptomycin. Cells were subcultured using colla-
genase/dispase (Boehringer Mannheim). Cells were irradiated be-
fore plating of bone marrow cells (3,000 rad, Cs-source). Methyl-
cellulose and myelocult medium (M5300) was purchased from
Stem Cell Technologies. Growth factors used in the platings are
IL-3 (1%), IL-6 (10 ng/ml), GM-CSF (1 ng/ml), SF (30 ng/ml),
Flt3L (20 ng/ml), Tpo (15 ng/ml), and erythropoietin (10 U/ml).
IL-3 is concentrated supernatant from WEHI-3b cells, all other
factors are recombinant.
 
Flow Cytometry.
 
Single cell suspensions were obtained in stain-
ing medium (HBSS 
 
1
 
 3% fetal calf serum, 10 mM Hepes, pH
 
 
 
7.0,
and 2 mM EDTA after ammonium chloride lysis of the red blood
cells, if necessary, and straining through a nylon mesh. Cells were
preincubated with mouse IgG (Sigma Chemical Co.) and stained
for 20 min with the various antibodies at the appropriate dilu-
tions, and, if necessary, incubated with secondary antibodies. Cells
were stained with antibodies against surface markers, followed,
when staining for the human BCL-2 protein, by fixation (5 min,
0.8% formaldehyde in PBS) and permeabilization (5 min, 0.3%
saponin in staining medium). Cells were then incubated for 3–16 h
with anti–BCL-2 antibody in 0.3% saponin in staining medium,
followed, if necessary, by incubation with the appropriate sec-
ondary antibody for 20 min. Sorting of HSC was modified from
previously published protocols (e.g., 30). In brief, bone marrow
cells are enriched for c-Kit
 
1
 
 cells using MACS-columns (Miltenyi
Biotechnology). The cells are stained with FITC-19XE5 (anti–
Thy1.1), lineage-cocktail, Texas red–E13-161-7 (anti–Sca-1), APC-
2B8 (anti–c-Kit), and biotin-3C11 (anti–c-Kit). Enriched cells are
sorted as described. The lineage cocktail consists of KT31.1 (anti–
CD3), GK1.5 (anti–CD4), 53-7.8 (anti–CD5), 53-6.7 (anti–CD8),
6B2 (anti–B220), Ter119 (anti–TER119), M1/70 (anti–Mac-1)
and 8C5 (anti–Gr-1). They are used either directly conjugated to
PE, or are visualized by secondary antibodies (anti–rat PE or
anti–rat Cy5PE). For analysis of reconstituted mice, peripheral
blood (
 
z
 
10 drops) was collected from the tail vein in PBS 
 
1
 
 5 mM
EDTA. Red cells were sedimented using 2% dextran (Pharmacia
LKB Biotechnology Inc.) in PBS, remaining red cells were lysed
with 0.15 ammonium chloride/0.01 M potassium bicarbonate.
The cells were divided into two aliquots, preblocked with mouse
IgG and stained with CD45.2-FITC, Gr-1-PE, Mac-1-biotin, and
CD45.1-APC or CD45.2-FITC, CD3-PE, B220-biotin, and
CD45.1-APC. Lineage analysis on organs of reconstituted mice
was done with the same antibody combinations. For analysis of
the relative contribution of injected cells to the HSC pool, bone
marrow was stained with the same lineage cocktail as above, fol-
lowed by anti–rat Cy5PE. The cells were then stained with
biotin3C11 (anti–c-Kit), followed by streptavidin-beads (Mil-
tenyi Biotechnology). The bone marrow was enriched for c-Kit
 
1
 
cells using MACS columns. The enriched cells were then stained 
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with CD45.2-FITC, Thy-1.1-PE, Sca-1-Texas red, and CD45.1-
APC. An aliquot of the enriched cells was stained with the normal
HSC markers including APC-2B8 (anti–c-Kit) to ensure that
 
,
 
10% of the HSC-gated cells were c-Kit
 
neg
 
. Labeled cells were
analyzed and sorted with a dual laser FACS
 
®
 
 Vantage (Becton
Dickinson Immunocytometry Systems), made available through
the FACS
 
®
 
 shared user group at Stanford University. Flow cytom-
etry data were analyzed using FACS
 
®
 
/Desk (Stanford University) or
FlowJo (Treestar Inc.). Dead cells were excluded from analysis by
their propidium iodide staining characteristics. Two parameter data
are presented as 5% probability plots with outliers.
The rat antibodies 53-7.3 (anti–CD5), 53-6.7 (anti–CD8), Ter-
119 (anti–erythro), GK 1.5 (anti–CD4), KT 31.1 (anti–CD3), 6B2
(anti–B220), M1/70 (anti–Mac-1), 8C5 (anti–GR-1), E13-161
(anti–Sca-1), 3C11 (anti–c-Kit), 2B8 (anti–c-Kit), ALI-4A2 (anti–
CD45.2), and A20.1.7 (anti–CD45.1) were prepared from the re-
spective hybridoma clones as were their conjugates. Secondary anti-
bodies were obtained from Caltag. Avidin Texas red was obtained
from Cappel Laboratories, anti–human BCL-2 (clone 124) from
Dako Corp.
Vital staining of cells with Hoechst 33342 to determine DNA
content was done as described (2).
 
Results
 
H2K-BCL-2–transgenic Mice Have More HSC.
 
LT-HSC in
this study are defined by the following combination of cell
 
surface markers: Thy-1.1
 
lo
 
, Sca-1
 
high
 
, c-Kit
 
high
 
, and Lin
 
neg
 
. Cells
with this phenotype, which form a rare population in whole
bone marrow, have been found to contain a population of
cells with long-term multilineage reconstitution potential.
The limit dilution dose for reconstitution with these cells is
 
z
 
10 cells injected i.v. (31).
 
 
 
Cells with short-term multilineage
reconstitution potential (ST-HSC) differ from the LT-HSC
population in increased, but low level, expression of certain
Lin-markers (initially Mac-1 followed by CD4), and are
present in larger numbers in whole bone marrow (31). When
bone marrow is stained for these HSC markers (Fig. 1, A
and B), the profiles for wild-type and H2K-
 
BCL
 
-2–trans-
genic mice are similar, except for relatively minor differences,
such as increased numbers of T cells (Thy-1.1
 
high
 
 cells). The
HSC populations as defined in wild-type mice can be easily
recognized in bone marrow from transgenic mice. Mor-
phologically, HSC from H2K-
 
BCL
 
-2–transgenic mice re-
semble those of wild-type mice (Fig. 1 C). LT-HSC are rel-
atively small and uniform in size, while ST-HSC are more
varied in size. Antibody staining for the presence of human
BCL-2 protein in cells with the LT-HSC surface pheno-
type shows that all cells express the transgene at high levels
(Fig. 1 D). This is in agreement with earlier data showing
high levels of expression in cells sorted for three (Thy-1.1,
Lin, Sca-1) of the four HSC markers, and with the fact that
these cells are protected against radiation-induced apoptosis
Figure 1. HSC FACS®-staining
profiles and expression of hBCL-2 in
HSC. (A) Staining profiles on WBM
of wild-type and H2K-BCL-2–trans-
genic mice for the four surface mark-
ers used to define HSC: Thy-1.1FITC,
LinPE, Sca-1TXR, and c-KitAPC. Boxed
areas indicate the gates within which
HSC are present. The two boxes in
the Thy-1.1 versus Lin plots depict
LT-HSC (Linneg, bottom) and ST-
HSC (Linlo, top). (B) As in A, except
that the plots depict populations
gated for Sca-11 and c-Kit1 (top)
and Thy-1.1lo and Linneg (bottom),
and thus allow assessment of the con-
tribution of each marker to the puri-
fication of the HSC population. (C)
Cytospin showing morphology of
Linneg and Linlo HSC sorted from
WT and H2K-BCL-2–transgenic
mice. May-Grünwald/Giemsa stain.
(D) Expression of the H2K-BCL-2
transgene in HSC from three differ-
ent founderlines. Bone marrow was
simultaneously stained for Thy1.1FITC,
LinCy5, Sca-1TXR, c-KitAPC, and
BCL-2PE, and analyzed using a modi-
fied FACS® Vantage. The histograms
depict BCL-2 staining in cells within
the LT-HSC gate (top) and ST-HSC
gates (bottom). Gray-filled histogram
depicts staining in wild-type cells,
open histograms in cells from
founderlines 1038, 1043, and 1053. 
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(30). All three founderlines used in this study (1038, 1043,
and 1053) have very similar levels of expression of the
transgene in HSC (Fig. 1 D). All of this is in agreement, but
doesn’t prove, that HSC in H2K-
 
BCL
 
-2–transgenic mice
 
have the same cell surface characteristics as wild-type HSC.
However, HSC cannot be defined by cell surface markers
alone, since these can vary (32). Therefore LT- and ST-HSC
from H2K-
 
BCL
 
-2–transgenic mice were tested for their
ability to repopulate lethally irradiated animals under limit-
dilution conditions. They do this at least as well as wild-
type HSC (see below). Quantitation of cells with HSC sur-
face phenotype in H2K-
 
BCL
 
-2–transgenic bone marrow
reveals an increase in their numbers, compared with that
present in wild-type bone marrow (Fig. 2). This is the case
both for cells with the LT-HSC surface phenotype (Lin
 
neg
 
)
and for cells with the ST-HSC surface phenotype (Lin
 
lo
 
).
As tabulated in Table I, the expansion of HSC is more dra-
matic in the LT-HSC compartment (2.4
 
3
 
 wild-type lev-
els) than in the ST-HSC compartment (1.7
 
3
 
 wild-type lev-
els). The spread in HSC numbers in H2K-
 
BCL
 
-2–transgenic
bone marrow is larger than that encountered in wild-type
littermates, as is demonstrated in Fig. 2 and the difference
in SD in Table I between wild-type and H2K-
 
BCL
 
-2. The
transgenic data on HSC numbers in Fig. 2, relative data,
and Table I, actual percentages of bone marrow, are based
on the analysis of mice from two different transgenic founder-
lines, 1038 and 1053. When analyzed separately, there is no
significant difference in the number of stem cells between
them (Fig. 2). Since there are no differences in the total
bone marrow cellularity between H2K-
 
BCL
 
-2–transgenic
mice and wild-type littermates (30), this increased frequency
of HSC means increased numbers of HSC in the bone
marrow.
 
Less HSC Are in Cycle in H2K-BCL-2–transgenic Mice.
 
BCL-2 has been reported to decrease the level of prolifera-
tion of cells overexpressing it (22). Since H2K-
 
BCL
 
-2–trans-
genic mice overexpress BCL-2 in HSC, it was investigated
whether this affects their cell cycle status. At any given time,
only a small percentage of LT-HSC are in the S/G
 
2
 
/M phases
of the cell cycle (has 
 
.
 
2n DNA content), while the majority
are in G
 
0
 
 or G
 
1
 
, which cannot be distinguished by measur-
ing the DNA content of the cells. However, it has recently
been established that in steady state hematopoiesis there is
no true resting population that stays in G
 
0 
 
for prolonged
periods of time. Over a period of 
 
z
 
30 d, all HSC can be
expected to go through a cell division at least once (1, 2).
Figure 2. HSC numbers in bone marrow from H2K-BCL-2 and wild-
type mice. Staining profiles showing Lin versus c-Kit staining for wild-
type (A) and transgenic (B) WBM. The boxed areas indicate HSC gates
for these markers for LT-HSC (left) and ST-HSC (right). (C) LT-HSC
numbers in bone marrow from wild-type and H2K-BCL-2–transgenic
mice. Open symbols represent wild-type mice, closed symbols H2K-
BCL-2–transgenic mice. Circles represent founderline 1038, squares
founderline 1053. Averages are indicated by the horizontal bars. (D) Same
as in B, but showing ST-HSC numbers.
 
Table I. HSC Numbers in Wild-Type and H2K-BCL-2 Bone Marrow, Shown as Average 6 SD
Percentage of WBM  
Linneg Linlo Linneg/lo Experiments Mice
nn
Wild-type 0.018 6 0.012 0.082 6 0.038 0.101 6 0.044 26 36
H2K-BCL-2 0.038 6 0.030 0.127 6 0.055 0.165 6 0.074 21 25
P 0.0032 0.0018 0.0006
Statistical analysis was done using Student’s t test. The numbers are based on analysis of 2–5 3 105 WBM cells per experiment stained for the HSC
markers, as depicted in Fig. 1. The data are based on analysis of animals from founderlines 1038 and 1053. The difference between the number of
experiments and the number of mice reflects pooled bone marrow samples in some experiments.257 Domen et al.
significantly from those of wild-type littermates in this re-
spect (data not shown), but the percentage of cells with
.2n DNA is also significantly reduced in transgenic thy-
mocytes when compared with those of wild-type mice.
When plotting the percentage of HSC against the percent-
age of cells in S/G2/M, there is no inverse correlation, sug-
gesting that the decrease in cycling HSC is not the conse-
quence of increased numbers of HSC (Fig. 3, C and D).
HSC Overexpressing BCL-2 Have Increased Plating Efficiency
In Vitro and Are Protected against Death Induced by Growth Factor
Deprivation.  To investigate whether apoptosis plays a role
in determining plating efficiency, HSC from H2K-BCL-
2–transgenic mice were sorted as either LT- or ST-HSC.
Single cells were plated on AC11 bone marrow stroma cells
using the FACS® Vantage single-cell deposition unit. The
wells were evaluated after 14 d for the presence of colonies
of hematopoietic cells. Under these conditions (stroma
feeder cells and medium with 5% FCS, but no added growth
factors), z30–50% of wild-type HSC plated will form he-
matopoietic colonies. As shown in Fig. 4 A, HSC from
H2K-BCL-2–transgenic mice outperformed wild-type HSC
in this assay. The plating efficiency of LT-HSC increases by
z20%, that of ST-HSC by z70%. Similar results were ob-
tained when sorted HSC were plated in methylcellulose in
the presence of a cocktail of hematopoietic growth factors
(IL-3, IL-6, GM-CSF, SF, and Epo). As shown in Fig. 4 B,
the plating efficiency of H2K-BCL-2–transgenic HSC is
increased over that of wild-type HSC in this assay.
To directly demonstrate that HSC from H2K-BCL-2–
transgenic mice are protected against apoptosis, growth fac-
tors (SF, Flt3L, IL-6, and Tpo) were added after a 70-h de-
lay to HSC plated as single cells in Terasaki wells, and the
proliferative response was compared with that of cells plated
under the same conditions, but with the factors added at
the time of plating, to compensate for the increased plating
efficiency of transgenic cells (see above). As shown in Fig. 4 C,
overexpression of BCL-2 protects HSC against cell death
induced by growth factor deprivation.
H2K-BCL-2 Cells Have a Competitive Advantage In Vivo.
In steady state hematopoiesis, the numbers of HSC and more
mature progenitors are carefully maintained. This can be
Figure 3. Cell cycle status of H2K-BCL-2–transgenic HSC. (A) Per-
centage of LT-HSC in bone marrow from wild-type and H2K-BCL-2–
transgenic mice that is in the S/G2/M phases of the cell cycle. Open sym-
bols represent wild-type mice, closed symbols H2K-BCL-2–transgenic
mice. Circles represent founderline 1038, triangles founderline 1043, and
squares founderline 1053. Data from 12 transgenic and 13 wild-type
mice, averages are indicated by the horizontal bars. At the bottom are
representative plots showing Hoechst staining of bone marrow cells
within the LT-HSC gates for wild-type (left) and transgenic (right) mice.
(B) Same as A, but showing ST-HSC. (Bottom) Relationship between
HSC numbers and cell cycle status for LT-HSC (C) and ST-HSC (D).
Table II. Cell-Cycle Status of HSC in Wild-Type and
H2K-BCL-2 Bone Marrow, Shown as Average 6 SD
.2n DNA (percentage of population) 
Linneg Linlo Linneg/lo WBM Mice
n
Wild-type 7.9 6 3.6 13.2 6 5.6 12.5 6 4.9 13.1 6 1.8 13
H2K-BCL-2 4.1 6 1.8 8.5 6 3.2 7.7 6 2.8 10.2 6 1.3 12
P 0.0035 0.0104 0.0049 ,0.0001
Statistical analysis was done using Student’s t test. The number of cells
in S/G2/M (.2n DNA content) are based on analysis of the HSC in
9 3 106 WBM cells stained for the HSC markers, as depicted in Fig. 1,
combined with Hoechst 33342. 
Less HSC in the bone marrow of H2K-BCL-2–transgenic
mice are in the S/G2/M phases of the cell cycle than are
seen in wild-type mice (Fig. 3, relative data, and Table II,
actual percentages). This is true both for LT-HSC (0.63
wild-type levels) and ST-HSC (0.73 wild-type levels).
There is no difference in this respect between the three
founderlines used in these studies (Fig. 3). Although less
than observed for HSC populations, there is also a differ-
ence in the percentage of cells in S/G2/M in whole bone
marrow (WBM). H2K-BCL-2–transgenic mice have 0.83
wild-type levels of cells with .2n DNA content (Table II)
in WBM. A difference in cell cycle status is not apparent
for all cell populations. Transgenic splenocytes do not differ258 Role of Apoptosis in Hematopoietic Stem Cell Homeostasis
accomplished by regulating proliferation, the decision be-
tween self-renewal or differentiation and apoptosis. To test
the importance of apoptosis in regulating the compartment
sizes of hematopoietic stem and progenitor cells, competi-
tive reconstitutions of LT-HSC from H2K-BCL-2–trans-
genic and wild-type mice were performed at various ratios,
ranging from 1:50 to 1:2. By using HSC that differ at the
CD45 allele (H2K-BCL-2 mice are CD45.2, wild-type mice
CD45.1), the fate of both can be followed in the same host.
The HSC are used to reconstitute an F1 host that expresses
both CD45.2 and CD45.1, which allows the distinction of
residual host cells from donor-derived hematopoietic cells
(Fig. 5 A). The contribution of both types of HSC to
hematopoiesis is measured at various times after reconstitution
by determining their ratio in peripheral blood. While BCL-2
overexpression can greatly increase the life span of especially
resting lymphocytes in vivo, this is not the case for myeloid
cells, which are short-lived, even when overexpressing BCL-2
(33). Their ratio thus is a good indication for relative stem cell
activity, even when comparing transgenic and wild-type
mice. As shown in Fig. 5 B, the contribution of H2K-BCL-2
HSC–derived cells to the total blood cell pool is higher than
expected from the input ratio of HSC. In addition, the con-
tribution of H2K-BCL-2–derived cells to the peripheral
blood pool increases over time. Fig. 5 B (right) shows that the
same is true for myeloid cells (Gr-11, Mac-11) in peripheral
blood. If wild-type and H2K-BCL-2–transgenic CD45.2
HSC are compared for their ability to compete against wild-
type CD45.1 HSC in vivo, the transgenic, but not wild-type,
CD45.2 cells have a competitive advantage (Fig. 5 C). Again,
this is both true when looking at total white blood cells (left)
and at myeloid cells (right) in peripheral blood. This differ-
ence is highly significant. When the results of three experi-
ments are combined, the CD45.2/CD45.1 ratio of myeloid
cells at 12–14-wk post-reconstitution does not differ from the
input ratio when both are wild-type (P 5 0.4334, n 5 10),
but it does increase when the CD45.2 cells are H2K-BCL-2
derived (P 5 0.0041, n 5 23).
Competitive Advantage after Reconstitution Includes HSC.  To
determine directly whether the increase in H2K-BCL-2
HSC–derived hematopoietic cells seen after competitive
reconstitution reflects an increase in transgenic HSC in the
bone marrow, the ratio of transgenic versus wild-type do-
nor-derived cells was determined for various cell popula-
tions, including HSC, in reconstituted animals. The results
for two representative animals are shown in Fig. 6. Fig. 6 A
shows the increase in transgenic/wild-type ratio (input ratio
is arbitrarily set at 1) in an F1 (CD45.13CD45.2) mouse 13
wk after reconstitution with 50 H2K-BCL-2 LT-HSC and
1,000 wild-type (WT) LT-HSC. Fig. 6 B shows these data
for a F1 mouse 60 wk after reconstitution with 12 H2K-
BCL-2–transgenic LT-HSC and 250,000 WT WBM cells.
As expected in both mice, the skewing of the donor cell ra-
tio in favor of H2K-BCL-2 HSC–derived cells is seen most
strongly in lymphoid populations. This reflects the activity
of BCL-2 in lymphoid cells, similar to what is seen in other
transgenic models (4–6). In both mice, the ratio of donor
myeloid cells is skewed toward overrepresentation of trans-
Figure 4. In vitro plating of HSC from H2K-BCL-2–transgenic and wild-
type mice. (A) Colony formation at 2 wk after plating of single HSC in 96-
well plates with confluent, irradiated, AC11 stroma cells. Solid black bars rep-
resent H2K-BCL-2, gray bars wild-type HSC. (Left) Data for LT-HSC;
(right) data for ST-HSC. Combined data from three experiments using
founderlines 1038 and 1053. (B) Colony formation after plating of single
sorted HSC in methylcellulose with IL-3, IL-6, SF, GM-CSF, and erythro-
poietin. Wells containing colonies of more than 50 cells were counted 8 d after
plating. (C) Survival of growth factor-deprived HSC from wild-type (gray
bars) and H2K-BCL-2 (solid bars) HSC. Single HSC were clones, sorted into
Terasaki wells containing myelocult M5300 medium without factors. SF,
Flt3L, IL-6, and Tpo were added after 70 h. The graph shows the surviving
(proliferating) cells as a percentage of the plating efficiency of nonstarved cells,
to compensate for the initial difference in plating efficiency (as illustrated in A
and B). One representative experiment is shown with data on 150 plated cells
per genotype for each cell type. Statistical analysis using Fisher’s Exact test.259 Domen et al.
genic cells, as is the case for HSC. Myeloid cells and HSC
are skewed to approximately the same extent, confirming
that myeloid cells are a good indicator of stem cell activity.
In this respect, there are no major differences between my-
eloid cells from peripheral blood, spleen, or bone marrow.
BCL-2 Overexpression Does Not Increase the Life Span of ST-
HSC–derived Clones. HSC can be functionally divided in cells
with the ability to self-renew and reconstitute all hemato-
poietic lineages for the life of an animal (LT-HSC) and cells
that can do this only for limited periods of time (ST-HSC).
To see whether overexpression of BCL-2 in ST-HSC can
expand the functional life span of ST-HSC–derived clones,
F1 mice (with respect to the CD45.1 and CD45.2 alleles)
were reconstituted with 10 wild-type and 10 H2K-BCL-
2–transgenic ST-HSC. The Gr-11, Mac-11 myeloid cells
derived from the different HSC were followed using the
CD45 markers, as discussed above. As depicted in Fig. 7,
transient reconstitution with myeloid cells from wild-type
and transgenic HSC is seen in the reconstituted mice. Re-
constitution levels are higher (4-wk time point) for H2K-
BCL-2–derived cells, but both transgenic and wild-type
clones have a limited life span and few ST-HSC–derived
myeloid cells can be seen after more than 12 wk.
Discussion
While the concepts of apoptotic versus necrotic cell death
have been formulated a long time ago, the more recent mo-
lecular characterization of the genes and proteins involved
Figure 5. Competitive repopulation in vivo using LT-HSC from H2K-
BCL-2–transgenic and wild-type mice. (A) Experimental model that allows
differential monitoring of wild-type and H2K-BCL-2–transgenic donor
cells and host cells. Donor cells are either CD45.2 (H2K-BCL-2) or
CD45.1 (wild-type), host cells are CD45.13CD45.2. All three populations
can easily be distinguished in the blood of reconstituted animals (right plot).
(B) Ratio in blood of total donor-derived cells in animals reconstituted with
two different combinations of wild-type and transgenic cells, as indicated in
the figure. The t 5 0 time point shows the HSC ratio used to reconstitute
lethally irradiated animals. Peripheral blood data are shown for 10, 18, and
36 wk after reconstitution. (Left) Ratios for total white blood cells; (right)
ratios for myeloid cells. Data points from 12 animals total. (C) Experimental
set-up as in B, except that CD45.2 HSC are either wild-type or H2K-
BCL-2 transgenic. (Left) Donor ratios for total white blood cells 14 wk af-
ter reconstitution with 50 CD45.2 HSC (wild-type or transgenic), 1,000
CD45.1 HSC (wild type) and 3 3 105 F1 bone marrow cells. (Gray bars)
Wild-type CD45.2 HSC; (black bars) H2K-BCL-2–transgenic CD45.2
HSC. (Right) Ratio of myeloid (Gr-11, Mac-11) donor-derived cells in
the same animals. Data are from seven reconstituted animals.
Figure 6. Comparative increase in H2K-BCL-2/wild-type donor ratio
in different cell populations, including HSC. Experimental set-up as in Fig.
5. The input (HSC) ratio was set as 1. (A) The overrepresentation of cells
derived from H2K-BCL-2 HSC in a mouse reconstituted with 12 H2K-
BCL-2–transgenic LT-HSC and 250,000 WT WBM cells 60 wk after
reconstitution. (B) The same data for an animal reconstituted with 50 H2K-
BCL-2–transgenic LT-HSC and 1,000 WT LT-HSC z14 wk after recon-
stitution. In both animals, the increased ratio of HSC mirrors that of my-
eloid cells, while the increase is much stronger for lymphoid cells.260 Role of Apoptosis in Hematopoietic Stem Cell Homeostasis
has led to a major increase in the appreciation of their im-
portance during normal and pathological development. Ap-
optosis plays an important role in hematopoiesis, and vari-
ous transgenic animal models have been generated to study
aspects of this. We have generated a transgenic mouse that
overexpresses BCL-2, the archetypal protein that protects
against different forms of apoptosis, in all hematopoietic
cells, including HSC. This was previously demonstrated for
radiation-induced cell death (30), and is extended in this
paper to cell death induced by growth factor deprivation;
HSC from H2K-BCL-2–transgenic mice are protected. We
have used this transgenic model to study the role of apop-
tosis in the maintenance of HSC in vivo. To guide the dis-
cussion of our finding that HSC have among their options
programmed cell death, Fig. 8 is provided.
The cell surface markers that are used to delineate HSC,
such as Thy-1.1low, Linneg/low, Sca-1high, and c-Kithigh are not
essential for HSC function, nor are they invariably associ-
ated with it. Under specific conditions (e.g., during devel-
opment) (34), or after 5-FU treatment (32), changes occur
in these staining profiles. Similar changes cannot be excluded
in transgenic mice. However, transplantation experiments
show that the cells with HSC surface markers in H2K-
BCL-2–transgenic mice are indeed HSC, and that they are
at least as efficient on a per-cell basis in repopulating le-
thally irradiated hosts as wild-type HSC.
BCL-2 overexpression in transgenic mice has been shown
to increase population sizes of various cell types. This was
initially demonstrated for lymphocytes (4–6), but has been
expanded to other cell populations, such as monocytes (7)
and neurons (35). The expansions tend to be most dramatic
in resting cells. This would be in line with the expansion in
transgenic HSC. Most stem cells are in the G1/G0 phases of
the cell cycle. The implication of this observation is that
HSC under steady state conditions are subject to regulation
by apoptosis.
The inability to maintain and expand long-term multi-
lineage reconstituting HSC as such in vitro, despite all the
factors and culture systems available, has led to the hypoth-
esis that such maintenance in vivo is strictly dependent on
particular microenvironments, and that the number of HSC
reflects the number of microenvironments. The limited in-
crease in HSC in the bone marrow of H2K-BCL-2–trans-
genic mice indicates that HSC, despite their resistance to
apoptosis, are not simply accumulating in ever larger num-
bers, but are still subject to regulation. Also, the variation in
bone marrow HSC numbers between animals is larger in
transgenic than in wild-type animals. This indicates that ad-
ditional events play a role in determining HSC numbers.
Since BCL-2 overexpression by itself does not prevent dif-
ferentiation in hematopoietic progenitor cells in vitro (24),
the limits on the increase of HSC numbers probably reflect
a limit in the HSC-supporting microenvironment. The vari-
ation in HSC numbers observed between different trans-
genic animals may reflect variations in the number of niches
available. However, it remains unclear what the regulatory
events are that set these limits. More insights may come
from some of the genetic analyses that are currently being
undertaken (reviewed in reference 8). The fact that ST-HSC
from H2K-BCL-2–transgenic mice have a limited life span
similar to that of wild-type HSC shows that the functional
life span of short-term stem cells is not limited seriously by
apoptosis. Commitment to further differentiation, rather than
apoptosis, seems to limit clonal life span.
At each HSC cell division, the two daughter cells choose
their cell fate, self-renewal or differentiation. This can be
done symmetrically (both cells adopt the same fate) or asym-
metrically (different fates). The balance determines the
number of stem cells. The cells that start differentiation regu-
late their cell numbers by extensive proliferation and apopto-
sis (36). Cell death rates seem to be higher at earlier stages of
differentiation (CFU-S level) than at later stages (CFC) (37).
Progress in characterizing the signaling pathways involved
in differentiation has been made; e.g., the notch family of
receptors (38–40). However, it is still unclear what deter-
mines whether a HSC self-renews or undergoes differentia-
tion. In traditional models of hematopoiesis, with most
HSC quiescent and only one or a few actively contributing,
limited regulation is necessary. However, more recent in-
sights into HSC dynamics [all HSC are cycling, albeit slowly
Figure 7. Competitive repopulation in vivo using ST-HSC from
H2K-BCL-2–transgenic and wild-type mice. Markers as in Fig. 5. Le-
thally irradiated CD45.13CD45.2 host animals were reconstituted with
10 transgenic ST-HSC (CD45.2), 10 wild-type ST-HSC (CD45.1), and
250,000 whole bone marrow cells from a CD45.13CD45.2 mouse. The
figure shows, as a percentage of nucleated blood cells, the myeloid cells
derived from transgenic ST-HSC (left) and wild-type ST-HSC (right).
Data from 10 reconstituted animals, the line shows the average reconsti-
tution at each time point, the symbols show the data for individual ani-
mals. The gray areas indicate the background staining in nonreconstituted
CD45.13CD45.2 mice. The difference in background levels is caused by
different staining characteristics of the CD45.1 and CD45.2 antibody
conjugates used. One representative experiment (out of three) is shown.
Figure 8. Model for regulation of HSC numbers. (A) HSC homeosta-
sis through balancing self-renewal and differentiation. (B) HSC homeo-
stasis by balancing self-renewal, differentiation, and apoptosis.261 Domen et al.
(1, 2), and all can be made to cycle rapidly under certain
conditions such as mobilization (41)] means that the fate of
HSC has to be decided continuously. Under steady state
conditions, z8% of the LT-HSC in C57Bl/Ka mice com-
plete cell division every day (2). Assuming 3 3 108 bone
marrow cells per mouse, and 0.01–0.02% (31) (Table I) of
these cells are LT-HSC, this means that, every day, 2–5 3
103 LT-HSC complete cell division, producing 4–10 3 103
cells. Under steady state conditions, half of these remain
LT-HSC, the remaining 2–5 3 103 cells either differentiate
or undergo apoptosis. The regulation of HSC numbers (the
decision to self-renew) has to be strictly regulated and en-
forced to prevent an unwanted expansion of HSC, with all
the risks of transformation that entails. In this paper, we
demonstrate that in addition to self-renewal and differentia-
tion, a third option is open to HSC under steady state condi-
tions in vivo: apoptosis.
It should be pointed out that while BCL-2 is a proto-
oncogene (42–44), the increase in HSC frequency in H2K-
BCL-2–transgenic mice (Fig. 2, Table I) and the increased
competitive reconstitution of transgenic HSC upon transfer
to irradiated hosts, did not result from the expansion of ma-
lignant clones; no stem-cell leukemias have been seen in
these mice. However, in line with other BCL-2–transgenic
mouse models, some of the H2K-BCL-2–transgenic mice
do develop myeloid or lymphoid leukemias late in life.
BCL-2 overexpression increases the length of the G1
phase of the cell cycle (22, 45). In H2K-BCL-2–transgenic
mice a similar phenomena is seen when transgenic HSC are
compared with wild-type HSC with respect to the number
of cells with .2n DNA. 5-Bromo-29-deoxyuridine label-
ing experiments in vivo confirm that HSC in H2K-BCL-
2–transgenic mice cycle more slowly (Cheshier, S.H., J.
Domen, and I.L. Weissman, manuscript in preparation).
The decrease in the percentage of HSC undergoing cell di-
vision is accompanied by increased numbers of HSC, thus
increasing the number of HSC offspring to slightly greater
than wild-type levels. This could indicate a homeostatic
adaptation, assuming that all dividing HSC contribute to
the peripheral pool, an assumption supported by the obser-
vation that donor ratios in HSC and peripheral myeloid
cells are similar. However, the fact that the proliferative
potential present in even a fraction of the normal HSC
number is sufficient to produce all the mature cells neces-
sary would seem to argue against the need for such a feed-
back. Also, as shown, there is no inverse correlation be-
tween the percentage of HSC with .2n DNA and the
percentage of HSC in bone marrow in either transgenic or
wild-type mice that would be expected if such a feedback
existed. If anything, especially in ST-HSC, the reverse is
true. One study addressing the correlation between pro-
genitor cell cycle kinetics and HSC numbers between dif-
ferent mouse strains fails to find a clear correlation for
HSC, but reports a negative correlation for progenitors
(46). However, this may differ from regulation of numbers
within an inbred strain. The reduction in cycling cells in
tissues such as thymus in the transgenic mice is similar to
other transgenic models (45).
The difference in engraftment between H2K-BCL-2–
transgenic and wild-type HSC in competitive repopula-
tions shows that transgenic stem cells have a competitive
advantage. The peripheral expansion of transgenic cells
seen in reconstituted animals reflects increased survival of
both HSC and more differentiated cells. However, direct
determination of HSC ratios in reconstituted animals shows
that the increase, and competitive advantage, starts at the
level of HSC. This relative increase in BCL-2 overexpress-
ing HSC does not only occur in the immediate post-recon-
stitution expansion period, when HSC are expanding rap-
idly, but continues gradually over a prolonged period of
time. While there are minor antigenic differences between
the CD45-congenic strains that are used for these competi-
tive reconstitutions, the fact that this increase is not seen
when wild-type CD45.2 cells are competed against wild-
type CD45.1 cells argues strongly against the selective ad-
vantage being at this level. Consequently, overexpression
of BCL-2, and thus protection against apoptosis, causes this
expansion. This demonstrates that, after reconstitution, ap-
optosis plays an important role in regulating and limiting
stem cell numbers. The main remaining challenge in this
and other systems is the identification of the signals that
control cell fate decisions of HSC.
We acknowledge Libuse Jerabek for excellent laboratory manage-
ment, Veronica Braunstein for preparing many of the antibodies
used, and Lu Hidalgo and Bert Lavarro for animal care and man-
agement. 
Parts of this work were supported by fellowship grants from the
Dutch Cancer Society/Koningin Wilhelmina Fonds (J. Domen)
and the Medical Scientist Training Program Grant 5T32GM07365
at Stanford University School of Medicine (S.H. Cheshier). The
major part of this work was supported by a grant from Systemix
Inc. and by United States Public Health Service grant CA42551.
Submitted: 25 August 1999
Revised: 7 October 1999
Accepted: 12 October 1999
References
1. Bradford, G.B., B. Williams, R. Rossi, and I. Bertoncello.
1997. Quiescence, cycling, and turnover in the primitive he-
matopoietic stem cell compartment. Exp. Hematol. 25:445–453.
2. Cheshier, S.H., S.J. Morrison, X. Liao, and I.L. Weissman.
1999. In vivo proliferation and cell cycle kinetics of long-term
hematopoietic stem cells. Proc. Natl. Acad. Sci. USA. 96:
3120–3125.
3. Morrison, S.J., A.M. Wandycz, K. Akashi, A. Globerson, and
I.L. Weissman. 1996. The aging of hematopoietic stem. Nat.
Med. 9:1011–1016.
4. McDonnell, T.J., N. Deane, F.M. Platt, G. Nunez, U. Jae-
ger, J.P. McKearn, and S.J. Korsmeyer. 1989. bcl-2-Immu-
noglobulin transgenic mice demonstrate extended B cell sur-
vival and follicular lymphoproliferation. Cell. 57:79–88.
5. Strasser, A., A.W. Harris, and S. Cory. 1991. bcl-2 transgene
inhibits T cell death and perturbs thymic self-censorship.
Cell. 67:889–899.
6. Sentman, C.L., J.R. Shutter, D. Hockenbery, O. Kanagawa,
and S.J. Korsmeyer. 1991. bcl-2 inhibits multiple forms of262 Role of Apoptosis in Hematopoietic Stem Cell Homeostasis
apoptosis but not negative selection in thymocytes. Cell. 67:
879–888.
7. Lagasse, E., and I.L. Weissman. 1997. Enforced expression of
Bcl-2 in monocytes rescues macrophages and partially re-
verses osteopetrosis in op/op mice. Cell. 89:1021–1031.
8. Domen, J., and I.L. Weissman. 1999. Self-renewal, differen-
tiation or death: regulation and manipulation of hematopoie-
tic stem cell fate. Mol. Med. Today. 5:201–208.
9. Chao, D.T., and S.J. Korsmeyer. 1998. BCL-2 family: regu-
lators of cell death. Annu. Rev. Immunol. 16:395–419.
10. Ashkenazi, A., and V.M. Dixit. 1998. Death receptors: sig-
naling and modulation. Science. 281:1305–1308.
11. Adams, J.M., and S. Cory. 1998. The Bcl-2 protein family:
arbiters of cell survival. Science. 281:1322–1326.
12. Vaux, D.L., and S.J. Korsmeyer. 1999. Cell death in devel-
opment. Cell. 96:245–254.
13. Bakhshi, A., J.P. Jensen, P. Goldman, J.J. Wright, O.W.
McBride, A.L. Epstein, and S.J. Korsmeyer. 1985. Cloning
the chromosomal breakpoint of t(14;18) human lymphomas:
clustering around JH on chromosome 14 and near a tran-
scriptional unit on 18. Cell. 41:899–906.
14. Cleary, M.L., S.D. Smith, and J. Sklar. 1986. Cloning and
structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/im-
munoglobulin transcript resulting from the t(14;18) translo-
cation. Cell. 47:19–28.
15. Tsujimoto, Y., and C.M. Croce. 1986. Analysis of the struc-
ture, transcripts, and protein products of bcl-2, the gene in-
volved in human follicular lymphoma. Proc. Natl. Acad. Sci.
USA. 83:5214–5218.
16. Vaux, D.L., S. Cory, and J.M. Adams. 1988. Bcl-2 gene pro-
motes haemopoietic cell survival and cooperates with c-myc
to immortalize pre-B cells. Nature. 335:440–442.
17. Vaux, D.L., H.L. Aguila, and I.L. Weissman. 1992. Bcl-2
prevents death of factor-deprived cells but fails to prevent
apoptosis in targets of cell mediated killing. Int. Immunol.
4:821–824.
18. Sutton, V.R., D.L. Vaux, and J.A. Trapani. 1997. Bcl-2 pre-
vents apoptosis induced by perforin and granzyme B, but not
that mediated by whole cytotoxic lymphocytes. J. Immunol.
158:5783–5790.
19. Reap, E.A., N.J. Felix, P.A. Wolthusen, B.L. Kotzin, P.L.
Cohen, and R.A. Eisenberg. 1995. bcl-2 transgenic Lpr mice
show profound enhancement of lymphadenopathy. J. Immu-
nol. 155:5455–5462.
20. Strasser, A., A.W. Harris, D.C. Huang, P.H. Krammer, and
S. Cory. 1995. Bcl-2 and Fas/APO-1 regulate distinct path-
ways to lymphocyte apoptosis. EMBO (Eur. Mol. Biol. Organ)
J. 14:6136–6147.
21. Traver, D., K. Akashi, I.L. Weissman, and E. Lagasse. 1998.
Mice defective in two apoptosis pathways in the myeloid lin-
eage develop acute myeloblastic leukemia. Immunity. 9:47–57.
22. Mazel, S., D. Burtrum, and H.T. Petrie. 1996. Regulation of
cell division cycle progression by bcl-2 expression: a potential
mechanism for inhibition of programmed cell death. J. Exp.
Med. 183:2219–2226.
23. Brady, H.J., G. Gil-Gomez, J. Kirberg, and A.J. Berns. 1996.
Bax alpha perturbs T cell development and affects cell cycle
entry of T cells. EMBO (Eur. Mol. Biol. Organ) J. 15:6991–
7001.
24. Fairbairn, L.J., G.J. Cowling, B.M. Reipert, and T.M. Dex-
ter. 1993. Suppression of apoptosis allows differentiation and
development of a multipotent hemopoietic cell line in the
absence of added growth factors. Cell. 74:823–832.
25. Kondo, M., K. Akashi, J. Domen, K. Sugamura, and I.L.
Weissman. 1997. Bcl-2 rescues T lymphopoiesis, but not B
or NK cell development, in common gamma chain-deficient
mice. Immunity. 7:155–162.
26. Akashi, K., M. Kondo, U. von Freeden-Jeffry, R. Murray,
and I.L. Weissman. 1997. Bcl-2 rescues T lymphopoiesis in
interleukin-7 receptor-deficient mice. Cell. 89:1033–1041.
27. Maraskovsky, E., L.A. O’Reilly, M. Teepe, L.M. Corcoran,
J.J. Peschon, and A. Strasser. 1997. Bcl-2 can rescue T lym-
phocyte development in interleukin-7 receptor-deficient mice
but not in mutant rag-12/2 mice. Cell. 89:1011–1019.
28. Bauman, J.G., P. de Vries, B. Pronk, and J.W. Visser. 1988.
Purification of murine hemopoietic stem cells and committed
progenitors by fluorescence activated cell sorting using wheat
germ agglutinin and monoclonal antibodies. Acta Histochem.
Suppl. 36:241–253.
29. Spangrude, G.J., and R. Scollay. 1990. Differentiation of he-
matopoietic stem cells in irradiated mouse thymic lobes. Kinet-
ics and phenotype of progeny. J. Immunol. 145:3661–3668.
30. Domen, J., K.L. Gandy, and I.L. Weissman. 1998. Systemic
overexpression of BCL-2 in the hematopoietic system pro-
tects transgenic mice from the consequences of lethal irradia-
tion. Blood. 91:2272–2282.
31. Morrison, S.J., and I.L. Weissman. 1994. The long-term re-
populating subset of hematopoietic stem cells is deterministic
and isolatable by phenotype. Immunity. 1:661–673.
32. Randall, T.D., and I.L. Weissman. 1997. Phenotypic and
functional changes induced at the clonal level in hematopoie-
tic stem cells after 5-fluorouracil treatment. Blood. 89:3596–
3606.
33. Lagasse, E., and I.L. Weissman. 1994. bcl-2 inhibits apoptosis
of neutrophils but not their engulfment by macrophages. J.
Exp. Med. 179:1047–1052.
34. Morrison, S.J., H.D. Hemmati, A.M. Wandycz, and I.L.
Weissman. 1995. The purification and characterization of fe-
tal liver hematopoietic stem cells. Proc. Natl. Acad. Sci. USA.
92:10302–10306.
35. Farlie, P.G., R. Dringen, S.M. Rees, G. Kannourakis, and
O. Bernard. 1995. bcl-2 transgene expression can protect
neurons against developmental and induced cell death. Proc.
Natl. Acad. Sci. USA. 92:4397–4401.
36. Necas, E., L. Sefc, G. Brecher, and N. Bookstein. 1995. He-
matopoietic reserve provided by spleen colony-forming units
(CFU-S). Exp. Hematol. 23:1242–1246.
37. Necas, E., L. Sefc, K. Sulc, E. Barthel, and H.J. Seidel. 1998.
Estimation of extent of cell death in different stages of normal
murine hematopoiesis. Stem Cells. 16:107–111.
38. Moore, K.A., B. Pytowski, L. Witte, D. Hicklin, and I.R.
Lemischka. 1997. Hematopoietic activity of a stromal cell
transmembrane protein containing epidermal growth factor-
like repeat motifs. Proc. Natl. Acad. Sci. USA. 94:4011–4016.
39. Varnum-Finney, B., L.E. Purton, M. Yu, C. Brashem-Stein,
D. Flowers, S. Staats, K.A. Moore, I. Le Roux, R. Mann, G.
Gray, et al. 1998. The notch ligand, Jagged-1, influences the
development of primitive hematopoietic precursor cells.
Blood. 91:4084–4091.
40. Jones, P., G. May, L. Healy, J. Brown, G. Hoyne, S. Delas-
sus, and T. Enver. 1998. Stromal expression of Jagged 1 pro-
motes colony formation by fetal hematopoietic progenitor
cells. Blood. 92:1505–1511.
41. Morrison, S.J., D.E. Wright, and I.L. Weissman. 1997. Cyclo-
phosphamide/granulocyte colony-stimulating factor induces
hematopoietic stem cells to proliferate prior to mobilization.263 Domen et al.
Proc. Natl. Acad. Sci. USA. 94:1908–1913.
42. Yang, E., and S.J. Korsmeyer. 1996. Molecular thanatopsis: a
discourse on the BCL2 family and cell death. Blood. 8:386–401.
43. Ekert, P.G., and D.L. Vaux. 1997. Apoptosis, haemopoiesis
and leukaemogenesis. Baillieres Clin. Haematol. 10:561–576.
44. Cory, S., D.L. Vaux, A. Strasser, A.W. Harris, and J.M. Ad-
ams. 1999. Insights from Bcl-2 and Myc: malignancy in-
volves abrogation of apoptosis as well as sustained prolifera-
tion. Cancer Res. 59:1685s–1692s.
45. O’Reilly, L.A., D.C. Huang, and A. Strasser. 1996. The cell
death inhibitor Bcl-2 and its homologues influence control
of cell cycle entry. EMBO (Eur. Mol. Biol. Organ.) J. 15:
6979–6990.
46. de Haan, G., and G. Van Zant. 1997. Intrinsic and extrinsic
control of hemopoietic stem cell numbers: mapping of a stem
cell gene. J. Exp. Med. 186:529–536.